Effectiveness and safety in behavioural and pharmacological interventions in patients of overactive bladder in real-world settings in India

Hrishikesh Wagholikar; Akhilesh Sharma; Mayur Mayabhate; Tejashri Jaju

doi:10.18203/2320-6012.ijrms20243705

Authors

Hrishikesh Wagholikar Wagholikar Kidney Hospital, Sangamner, Maharashtra, India
Akhilesh Sharma Alkem Laboratories Ltd, Mumbai, Maharashtra, India
Mayur Mayabhate Alkem Laboratories Ltd, Mumbai, Maharashtra, India
Tejashri Jaju Alkem Laboratories Ltd, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243705

Keywords:

Overactive bladder, Real world, Efficacy, Combined therapy, Overactive bladder symptom score

Abstract

Background: Overactive bladder (OAB) is a urinary bladder condition causing bladder dysfunction. OAB commonly presents the symptoms of nocturia, incontinence, increased urinary frequency, and urinary urgency with a prevalence of 15.5 % among the Indian population.

Methods: This retrospective observational study assessed the efficacy and safety of combined behavioral and pharmacotherapy in managing OAB in the elderly adult population. Data was collected from digital and paper-based medical records of patients aged 40 years or older. Enrolled patients reported symptoms of OAB for at least 3 months. Efficacy and safety outcomes were assessed using overactive bladder symptom score (OABSS) measured at baseline and after an 8-week follow-up period.

Results: The mean OABSS reduced from 12.39±2.4 at baseline to 8.06±3.46 at 8 weeks post-intervention. A mean difference of 4.33 points (p<0.0001) was observed in OABSS scores between baseline and the 8-week follow-up. During the follow-up, no adverse events were observed.

Conclusions: A mean reduction of 4.33 points in OABSS scores was observed between baseline and the 8-week follow-up, showing a significant decrease in symptom severity with combined behavioral and pharmacological therapy. To assess the long-term efficacy and safety of combined behavioral and pharmacological interventions in OAB patients, studies with large sample sizes are required. This will provide a better understanding to healthcare professionals to optimize OAB management and overcome side effects seen with conventional medications.

Metrics

Metrics Loading ...

References

Burgio KL, Kraus SR, Johnson TM. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180(3):411.

Shawahna R. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study. BMC Urol. 2021;2:142.

Pal M, Bandyopadhyay S, Roy A. Overactive bladder symptom score – translation and linguistic validation in Bengali. J Fam Med Prim Care. 2022;11(1):79.

Przydacz M, Gasowski J, Grodzicki T, Chlosta P. Lower urinary tract symptoms and overactive bladder in a large cohort of older poles—a representative tele-survey. J Clin Med. 2023;12(8):2859.

Hagovska M, Svihra J. Evaluation of silodosin and pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder (silodosing) study protocol (spirit compliant). Int J Environ Res Public Health. 2021;18(21):11426.

Chen JL, Chen SF, Jiang YH, Kuo HC. Practical points in the medical treatment of overactive bladder and nocturia in the elderly. Tzu Chi Med J. 2016;28(1):1-5.

Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006;3:175.

Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63(8):1177-91.

Scarneciu I, Lupu S, Bratu O. Overactive bladder: A review and update. Exp Ther Med. 2021;22(6):1444.

Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, et al. Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the beside clinical trial. Patient. 2017;10(6):677-86.

Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic Changes Associated with Behavioral and Drug Treatment of Urge Incontinence in Older Women. J Am Geriatr Soc. 2002;50(5):808-16.

Xu D, Zhao M, Huang L, Wang K. Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis. Health Qual Life Outcomes. 2018;16(1):14.

Chuang FC, Hsiao SM, Kuo HC. The Overactive Bladder Symptom Score, International Prostate symptom score–storage subscore, and urgency severity score in patients with overactive bladder and hypersensitive bladder: which scoring system is best? Int Neurourol J. 2018;22(2):99-106.

Qudah S, Abufaraj M, Farah R. The prevalence of overactive bladder and its impact on the quality of life: A cross-sectional study. Arab J Urol. 2024;22(1):39-47.

Chiu A, Huang M, Wang C, Kuo H. Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus. Int J Urol. 2012;19(11):995-1001.

Xu D, Cheng R, Ma A, Zhao M, Wang K. Toileting behaviors and overactive bladder in patients with type 2 diabetes: a cross-sectional study in China. BMC Urol. 2017;17(1):42.

Akbar A, Liu K, Michos ED. Association of overactive bladder with hypertension and blood pressure control: the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2022;35(1):22-30.

Hubeaux K, Deffieux X, Ismael SS, Raibaut P, Amarenco G. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol. 2007;178(6):2483-7.

Liao W, Jaw F. A noninvasive evaluation of autonomic nervous system dysfunction in women with an overactive bladder. Int J Gynecol Obstet. 2010;110(1):12-7.

Muntner P, Shimbo D, Carey RM. Measurement of blood pressure in humans: a scientific statement from the American heart association. Hypertension. 2019;73:5.

Burgio KL, Kraus SR, Menefee S. Behavior Therapy to Enable Drug Discontinuation in the Treatment of Urge Incontinence: A Randomized Controlled Trial. Published online 2011.

Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012;4(6):315-24.

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558-63.

Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome: SOLIFENACIN AND SYMPTOMS OF OAB. Int J Clin Pract. 2006;60(8):959-66.

Wolff G, Kuchel G, Smith P. Overactive bladder in the vulnerable elderly. Res Rep Urol. 2014;6:131-8.

Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017;11:463-7.

Drake MJ, Chapple C, Esen AA. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE). Eur Urol. 2016;70(1):136-45.

Herschorn S, Chapple CR, Abrams P. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study). BJU Int. 2017;120(4):562-75.

Abrams P, Kelleher C, Staskin D. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35(5):827-38.

Dorey G. Male patients with lower urinary tract symptoms 2: Treatment. Br J Nurs. 2000;9(9):553-8.

Selo‐Ojeme D, Pathak S, Aziz A, Odumosu M. Fluid and caffeine intake and urinary symptoms in the UK. Int J Gynecol Obstet. 2013;122(2):159-60.

Rantell A, Vosloo R. Managing urinary incontinence in women. Pract Nurs. 2008;19(5):235-40.

Callan L, Thompson DL, Netsch D. Does increasing or decreasing the daily intake of water/fluid by adults affect overactive bladder symptoms? J Wound Ostomy Continence Nurs. 2015;42(6):614-20.

Ko IG, Lim MH, Choi PB, Kim KH, Jee YS. Effect of long-term exercise on voiding functions in obese elderly women. Int Neurourol J. 2013;17(3):130.

Aukee P, Immonen P, Laaksonen DE, Laippala P, Penttinen J, Airaksinen O. The effect of home biofeedback training on stress incontinence. Acta Obstet Gynecol Scand. 2004;83(10):973-7.

Alwis US, Monaghan TF, Haddad R. Dietary considerations in the evaluation and management of nocturia. F1000Research. 2020;9:165.

Hobson RM, Maughan RJ. Hydration status and the diuretic action of a small dose of alcohol. Alcohol. 2010;45(4):366-73.

Chun JY, Song M, Han JY, Na S, Hong B, Choo MS. Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice. overactive bladder. Int Neurourol J. 2014;18(1):23–30.

Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Ueno K, et al. Cognitive behavioral therapy for overactive bladder in women: study protocol for a randomized controlled trial. BMC Urol. 2020;20(1):129.